MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs.
On the company’s earnings call, Chief Executive Officer Ofer Gonen said MediWound “continued to execute against our key strategic priorities,” including moving EscharEx toward commercialization and expanding the global role of NexoBrid. He said the timeline for the EscharEx Phase III VALUE study has shifted by one quarter, but added that “the underlying momentum behind the program continues to strengthen.”